<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918355</url>
  </required_header>
  <id_info>
    <org_study_id>19-1130</org_study_id>
    <secondary_id>20-0072</secondary_id>
    <nct_id>NCT04918355</nct_id>
  </id_info>
  <brief_title>A Health System Wide Evaluation of Clinical Decision Support Tools to Improve PDMP Utilization and Patient Outcomes</brief_title>
  <official_title>A Health System Wide Evaluation of Mandated Use and Clinical Decision Support Tools to Improve PDMP Utilization and Patient Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study comparing three clinical decision support (CDS) tools to enhance care by&#xD;
      easing health care provider review of the Colorado prescription drug monitoring program&#xD;
      (PDMP) prior to prescribing opioids (pain medications often called narcotics) or&#xD;
      benzodiazepines (sedatives or muscle relaxants). The tools screen information from the PDMP&#xD;
      (a statewide database of filled controlled medication) and a patient's medical record to&#xD;
      identify high-risk factors for overdose.&#xD;
&#xD;
      The tools only appear when relevant, are purely informational to facilitate an evidence-based&#xD;
      practice (PDMP review) and do not dictate care or suggest changes in treatment.&#xD;
&#xD;
      The study will track how each of the tools are used and if providers use the PDMP. Secondary&#xD;
      outcomes include if a controlled medication prescription was written and future opioid use by&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior research by this team has shown that when emergency department (ED) prescribers are&#xD;
      less likely to prescribe an opioid analgesic to patients at high-risk of overdose or misuse&#xD;
      when they consult the Colorado Prescription Drug Monitoring Program (PDMP). Despite extensive&#xD;
      work to reduce workflow and accessibility barriers to use of the PDMP, the majority of&#xD;
      providers still do not use the PDMP when making prescription decisions. Clinical decision&#xD;
      support (CDS) that is embedded in the Electronic Health Record (EHR) has promise as a tool to&#xD;
      increase PDMP use, advance presentation of important PDMP data to providers and improve&#xD;
      opioid safety without interrupting provider workflow.&#xD;
&#xD;
      This pragmatic, cluster-randomized study is designed to determine if:&#xD;
&#xD;
        -  CDS tools that deliver focused, timely clinical information about high risk&#xD;
           prescriptions to prescribers can improve use of the PDMP&#xD;
&#xD;
        -  The use of focused CDS tools can decrease high-risk opioid prescribing&#xD;
&#xD;
        -  The use of focused CDS tools is associated with better patient outcomes: decreasing&#xD;
           high-risk, long-term, and aberrant opioid use&#xD;
&#xD;
      Specifically, we will test the hypotheses that:&#xD;
&#xD;
        1. Focused CDS tools will increase the percentage of high-risk prescriptions with a PDMP&#xD;
           review, compared to the control group.&#xD;
&#xD;
        2. Focused CDS tools will decrease the percentage of high-risk controlled medication&#xD;
           prescriptions, compared to the control group.&#xD;
&#xD;
      The alerts will fire for discharge prescriptions in all system emergency departments,&#xD;
      inpatient facilities and ambulatory care facilities. Evaluation of patient risk as described&#xD;
      below will be conducted automatically and for two of the three visible alerts, the provider&#xD;
      will only see the alert if the patient meets high risk criteria. Providers in emergency&#xD;
      departments and inpatient facilities will be randomized at the individual level, while&#xD;
      providers in the ambulatory setting will be randomized as &quot;clinics&quot; defined as groups of&#xD;
      providers who prescribe at the same site or set of sites (such as a series of primary care&#xD;
      clinics staffed by an identifiable set of providers). Approximately 4000 providers will be&#xD;
      included, based on historical staffing of UCHealth facilities.&#xD;
&#xD;
      Patients will be identified on the basis of an encounter with an enrolled provider and will&#xD;
      not be further randomized. Automated risk assessment steps will be carried out on patients&#xD;
      seen at included UCHealth facilities in the course of the year-long activation of the alerts.&#xD;
      Based on historical patient counts, this is approximately 950,000 unique patients. Visit data&#xD;
      will be retrospectively collected. This population is expected to be approximately 200,000&#xD;
      individuals.&#xD;
&#xD;
      The CDS only changes the provider interface with the PDMP and does not include any treatment&#xD;
      recommendations or limit providers in any way from providing opioids or benzodiazepines if&#xD;
      that is the best course of action in the provider's clinical judgement. Providers are not&#xD;
      required to check the PDMP. The CDS is designed to enable access to the PDMP specifically&#xD;
      focused on high risk prescriptions.&#xD;
&#xD;
      As the study implements an automated CDS, which is routinely introduced into clinical&#xD;
      practice with no consent process, and does not make any treatment recommendations or&#xD;
      requirements, it is being conducted at the provider level under a waiver of informed consent.&#xD;
      Patient outcome determination will be conducted as secondary research, with patients to be&#xD;
      included identified on the basis of their interaction with an enrolled health care provider.&#xD;
      Only data collected as part of routine care will be collected to measure secondary outcomes.&#xD;
      All patient data will be de-identified by the research team's Honest Broker and a&#xD;
      de-identified data set provided for analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of PDMP checks for high-risk prescriptions</measure>
    <time_frame>Total over the course of one year</time_frame>
    <description>Differences between groups in the percentage of opioid or benzodiazepine prescriptions with one or more high risk criteria for whom the healthcare provider consults the Prescription Drug Monitoring Program (PDMP) prior to signing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of high-risk controlled medication prescriptions</measure>
    <time_frame>Total over the course of one year</time_frame>
    <description>Differences between groups in the percentage of patients with one or more high risk criteria who go on to receive an opioid or benzodiazepine prescription after the CDS alert fires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-prescription PDMP use</measure>
    <time_frame>Total over the course of one year</time_frame>
    <description>Differences between groups in the frequency with which providers check the PDMP for high risk (by alert criteria) and low risk prescriptions respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term opioid use</measure>
    <time_frame>Total over the course of one year</time_frame>
    <description>Differences in the percentage of patients seen by providers in each group who go on to long term or aberrant use (combined metric) of controlled medications.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Medication Abuse</condition>
  <arm_group>
    <arm_group_label>Provider Group 1: no alert</arm_group_label>
    <description>Control group to enable tracking of temporal changes in prescribing. Providers will not see any alert.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Provider Group 2: Mandated alert</arm_group_label>
    <description>Control group where providers will see a generic pop-up alert within the Electronic Health Record (EHR) whenever they initiate an opioid or benzodiazepine prescription without recording use of the PDMP. Patient risk factors are not assessed or presented in the alert. Providers in ambulatory clinics will not be assigned to this group. Alerts do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Provider Group 3: PDMP alert</arm_group_label>
    <description>Providers will see a pop-up alert within the EHR when they initiate an opioid or benzodiazepine prescription without recording use of the PDMP and patients have one or more positive risk factors based on past/current prescriptions received. Patient risk factors are assessed and presented in the alert. Risk factors included are numbers of active or recent opioid and benzodiazepine prescriptions, overlapping prescriptions, co-prescribing of benzodiazepines and opioids, and use of long-acting opioids in opioid na√Øve patients.&#xD;
Alerts are seen only once regardless of the number of positive risk factors and do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Provider Group 4: PDMP + EHR alert</arm_group_label>
    <description>Providers will see a pop-up alert within the EHR when they initiate an opioid or benzodiazepine prescription without recording use of the PDMP and patients have one or more positive risk factors based on both prescriptions and other factors recorded in the patient's Electronic Health Record. Patient risk factors are assessed and presented in the alert. Risk factors included the risks described as in Group 3, along with a history of accidental opioid overdose, diagnosis of Opioid Use Disorder, multiple recent acute care incidents with opioid use, or high risk psychiatric diagnoses.&#xD;
Alerts are seen only once regardless of the number of positive risk factors and do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical Decision Support (CDS) alerts</intervention_name>
    <description>CDS alerts are pop-up boxes integrated into the EHR. Each alert provides patient specific information, a link to the PDMP, instructions on how to dismiss the alert, a link to study-specific educational website, and a comment field.</description>
    <arm_group_label>Provider Group 2: Mandated alert</arm_group_label>
    <arm_group_label>Provider Group 3: PDMP alert</arm_group_label>
    <arm_group_label>Provider Group 4: PDMP + EHR alert</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Provider population: Health care providers in Colorado who work in the University of&#xD;
        Colorado Health (UCHealth) system.&#xD;
&#xD;
        Patient population: Residents and visitors to the state of Colorado who seek healthcare&#xD;
        within the UCHealth system.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Two populations are included in the study description. Providers and the patients seen by&#xD;
        those providers.&#xD;
&#xD;
        Providers are randomized to one of the four groups described previously.&#xD;
&#xD;
        Provider Inclusion Criteria:&#xD;
&#xD;
          -  Licensed health care providers within the UCHealth system with a history (previous&#xD;
             year) of prescribing opioids and/or benzodiazepines.&#xD;
&#xD;
        Provider Exclusion Criteria:&#xD;
&#xD;
          -  Majority of prescribing is done at a facility outside the state of Colorado&#xD;
&#xD;
          -  Provider specialty of oncology or pediatrics as recorded in the EHR&#xD;
&#xD;
          -  Provider in an ambulatory clinic where a total of &lt;50 opioid or benzodiazepine&#xD;
             prescriptions were written in the year before study initiation&#xD;
&#xD;
        Patient Inclusion Criteria:&#xD;
&#xD;
          -  Patient seen by a randomized provider within the UCHealth system who may receive an&#xD;
             opioid prescription&#xD;
&#xD;
        Patient Exclusion Criteria:&#xD;
&#xD;
          -  Less than 12 years of age or greater than 89 years of age at the time of the first&#xD;
             study associated visit&#xD;
&#xD;
          -  Active oncology or sickle cell diagnosis&#xD;
&#xD;
          -  Active end of life care (defined as discharge to hospice or palliative care facility&#xD;
             or specific palliative care orders in the medical record)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jason A Hoppe, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheryl Napier</last_name>
    <phone>(303)724-4214</phone>
    <email>cheryl.napier@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jason A Hoppe, DO</last_name>
    <email>jason.hoppe@cuanschutz.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Napier</last_name>
      <phone>303-724-4214</phone>
      <email>cheryl.napier@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Jason A Hoppe, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

